Cancer Immunology, Immunotherapy

, Volume 54, Issue 12, pp 1153–1161

Regulatory T cells and tumor immunity

  • Subhasis Chattopadhyay
  • Nitya G. Chakraborty
  • Bijay Mukherji
Review

Abstract

Central deletion of “self-reactive” T cells has been the textbook paradigm for inducing “self-tolerance” in the periphery and the concept of a role of T cell-mediated suppression in this process has long been controversial. A decisive shift in the opinion on suppressor T cells has lately occurred with the observations of Sakaguchi’s group that linked a class of CD4+CD25+ T cells to the prevention of autoimmunity from neonatal thymectomy in mice. These CD4+CD25+ T cells have been named T regulatory (Treg) cells. They are believed to be selected in the thymus as an anti-self repertoire. Hence they were referred to as natural T regulatory (nTreg) cells. Presently, in addition to their role in autoimmunity, they are believed to exert regulatory function in infection, in transplantation immunity as well as in tumor immunity. In contrast to these nTreg cells, another class of CD4+ Treg cells also exercises regulatory function in the periphery. These Treg cells are also CD4+ T cells and after activation they also become phenotypically CD4+CD25+. They are, however induced in the periphery as Treg cells. Hence, they are termed as induced Treg (iTreg) cells. There are major differences in the biology of these two types of Treg cells. They differ in their requirements for activation and in their mode of action. Nonetheless, evidence indicates that both nTreg cells and iTreg cells are involved in the control of tumor immunity. The question of how to circumvent their regulatory constraints, therefore, has become a major challenge for tumor immunologists.

Keywords

Treg Tumor immunity 

Abbreviations

Treg

T regulatory

nTreg

Natural Tregulatory

iTreg

Inducible T regulatory

Ts

T suppressor

APC

Antigen presenting cell

CTL

Cytolytic T lymphocytes

MHC

Major histocompatibility complex

IL

Interleukin

IFN

Interferon

TAA

Tumor associated antigen

References

  1. 1.
    Gershon RK, Kondo K (1970) Cell interactions in the induction of tolerance: the role of thymic lymphocytes. Immunology 18:723PubMedGoogle Scholar
  2. 2.
    Moller G (1988) Do suppressor T cells exist? Scand J Immunol 27:247PubMedGoogle Scholar
  3. 3.
    Sakaguchi S (2004) Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 22:531CrossRefPubMedGoogle Scholar
  4. 4.
    Shevach EM (2001) Certified professionals: CD4+CD25+ suppressor T cells. J Exp Med 193:F41CrossRefPubMedGoogle Scholar
  5. 5.
    Sakaguchi S, Takahasi T, Nisizuka Y (1982) Study on cellular events in post-thymectomy autoimmune oophoritis in mice: I. Requirement of Lyt-1 effector cells for oocyte damage after adoptive transfer. J Exp Med 156:156Google Scholar
  6. 6.
    Sakaguchi S, Takahasi T, Nisizuka Y (1982) Study on cellular events in post-thymectomy autoimmune oophoritis in mice: II. Requirement of Lyt-1 effector cells in normal female mice for the prevention of oophoritis. J Exp Med 156:1577CrossRefPubMedGoogle Scholar
  7. 7.
    Sakaguchi S, Fukuma K, Kuribiashi K, Masuda T (1985) Organ specific autoimmunie diseases induced in mice by elimination of T cell subsets. I. Evidence for the active participation of T cells in natural self-tolerance: deficit of a subset as possible cause of autoimmunity. J Exp Med 161:72CrossRefPubMedGoogle Scholar
  8. 8.
    Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M (1995) Immunologic self tolerance maintained by activated T cells expressing IL-2 receptor a-chain (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 155:1151PubMedGoogle Scholar
  9. 9.
    Berendt MJ, North RJ (1980) T-cell-mediated suppression of antitumor immunity. An explanation for progressive growth of an immunogenic tumor. J Exp Med 151:69CrossRefPubMedGoogle Scholar
  10. 10.
    North RJ (1985) Down-regulation of the antitumor immune response. Adv Cancer Res 45:1PubMedGoogle Scholar
  11. 11.
    Mukherji B, Wilhelm SA, Guha A, Ergin MT (1986) Regulation of cellular immune response against autologous human melanoma. I. Evidence for cell-mediated suppression of in vitro cytotoxic immune response. J Immunol 136:1888PubMedGoogle Scholar
  12. 12.
    Mukherji B, Nashed AL, Guha A, Ergin MT (1986) Regulation of cellular immune response against autologous human melanoma. II. Mechanism of induction and specificity of suppression. J Immunol 136:1893PubMedGoogle Scholar
  13. 13.
    Mukherji B, Guha A, Chakraborty NG, Sivanandham M, Nashed AL, Sporn JR, Ergin MT (1989) Clonal analysis of cytotoxic and regulatory T cell responses against human melanoma. J Exp Med 169:1961CrossRefPubMedGoogle Scholar
  14. 14.
    Sakaguchi S (2000) Regulatory T cells: key controllers of immunologic self-tolerance. Cell 26:455CrossRefGoogle Scholar
  15. 15.
    Sakaguchi S, Sakaguchi N, Shimizu J, Yamazaki Y, Sakihama T, Itoh M, Kuniyasu Y, Nomura T, Toda M, Takahasi T (2001) Immunologic tolerance maintained by CD25+CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev 182:18CrossRefPubMedGoogle Scholar
  16. 16.
    Piccirillo CA, Shevach EM (2004) Naturally-occurring CD4+CD25+ immunoregulatory T cells: central players in the arena of peripheral tolerance. Semin Immunol 16:81CrossRefPubMedGoogle Scholar
  17. 17.
    O’Garra A, Vieira P (2004) Regulatory T cells and mechanisms of immune system control. Nature Med 10:801CrossRefPubMedGoogle Scholar
  18. 18.
    Thompson C, Powrie F (2004) Regulatory T cells. Curr Opin Pharmacol 4:408CrossRefPubMedGoogle Scholar
  19. 19.
    Bach JF (2003) Regulatory T cells under scrutiny. Nature Rev Immunol 3:189CrossRefGoogle Scholar
  20. 20.
    Ehrlich P (1909) Nederlandsch Tijdschrift voor Geneeskunde: Ueber den jetzigne Stand Der Karzinomforchung. Weekblad Jaargang Eerst helft 5:273Google Scholar
  21. 21.
    Srivastava PK, Old LJ (1988) Individually distinct transplantation antigens of chemically induced mouse tumors. Immunol Today 9:78CrossRefPubMedGoogle Scholar
  22. 22.
    Boon T, van der Bruggen P (1996) Human tumor antigens recognized by T lymphocytes. J Exp Med 183:725CrossRefPubMedGoogle Scholar
  23. 23.
    Rosenberg SA (1997) Cancer vaccines based on the identification of genes encoding cancer regression antigens. Immunol Today 18:175CrossRefPubMedGoogle Scholar
  24. 24.
    Novellino L, Castelli C, Parmiani G (2005) A listing of human tumor antigens recognized by T cells. Cancer Immunol Immunother 54:187CrossRefPubMedGoogle Scholar
  25. 25.
    Gilboa E (2004) The promise of cancer vaccines. Nat Rev Cancer 4:401CrossRefPubMedGoogle Scholar
  26. 26.
    Dunn GP, Old LJ, Schreiber RD (2004) The three Es of cancer immunoediting. Annu Rev Immunol 22:329CrossRefPubMedGoogle Scholar
  27. 27.
    Marincola FM, Jaffee EM, Hiclin DJ, Ferrone S (2000) Escape of human solid tumors from T cell-cell recognition: molecular mechanisms and functional significance. Adv Immunol 74:181PubMedGoogle Scholar
  28. 28.
    Pawlec (2004) Tumor escape from the immune response. Cancer Immunol Immunother 53:843PubMedGoogle Scholar
  29. 29.
    Ahmad M, Rees RC, Ali SA (2004) Escape from immunotherapy; possible mechanisms that influence tumor regression/progression. Cancer Immunol Immunother 53:844CrossRefPubMedGoogle Scholar
  30. 30.
    Anichini A, Vigetti C, Mortini R (2004) The paradox of T cell-mediated antitumor immunity in spite of poor clinical outcome in human melanoma. Cancer Immunol Immunother 53:855CrossRefPubMedGoogle Scholar
  31. 31.
    Whiteside TL (2004) Down-regulation of the z-chain expression in T cells: a biomarker of prognosis in cancer? Cancer Immunol Immunother 53:865PubMedGoogle Scholar
  32. 32.
    Chakraborty NG, Li L, Sporn JR, Kurtzman SH, Ergin MT, Mukherji B (1999) Emergence of Th2 type CD4+ T cell response to repetitive stimulation with antigen and antigen presenting cells, in vitro: Implications in designing tumor vaccines. J Immunol 162:5576PubMedGoogle Scholar
  33. 33.
    Mukherji B, Guha A, Loomis R, Ergin MT (1987) Cell-mediated amplification and down-regulation of cytotoxic immune response against autologous human cancer. J Immunol 138:1987PubMedGoogle Scholar
  34. 34.
    Chakraborty NG, Twardzik DR, Sivanandham M, Ergin MT, Hellstrom KE, Mukherji B (1990) Autologous melanoma-induced activation of regulatory T cells that suppress cytolytic response. J Immunol 145:2359PubMedGoogle Scholar
  35. 35.
    Mukherji B, Chakraborty NG, Sivanandham M (1990) T cell clones that react against human tumors. Immunol Rev 116:33PubMedGoogle Scholar
  36. 36.
    Groux H, O’Garra A, Bigler M, Rouleau M, Antonenko S, de Vries JE, Roncarolo MG (1997) A CD4+ T cell subset inhibits antigen specific T cell responses and prevents colitis. Nature 389:737CrossRefPubMedGoogle Scholar
  37. 37.
    Roncarolo MG, Bachetta R, Bordignon C, Narula S, Levings MK (2001) Type 1 T regulatory cells. Immunol Rev 182:68CrossRefPubMedGoogle Scholar
  38. 38.
    Chakraborty NG, Chattopadhyay S, Mehrotra S, Chhabra A, Mukherji B (2004) Regulatory T cells response and tumor vaccine induced CTL in human melanoma. Human Immunol 65:794CrossRefPubMedGoogle Scholar
  39. 39.
    Wang HY, Lee DA, Peng G, Guo Z, Li Y, Kiniwa Y, Shevach EM, Wang RF (2004) Tumor specific human CD4+ regulatory T cells and their ligands: implications for immunottherapy. Immunity 20:107CrossRefPubMedGoogle Scholar
  40. 40.
    Shimizu J. Yamazaki S, Sakaguchi S (1999) Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J Immunol 163:5211PubMedGoogle Scholar
  41. 41.
    Onizuka S, Tawara I, Shimizu J, Sakaguchi S, Fujita T, Nakayama E (1999) Tumor rejection by in vivo administration of anti-CD25 (interleukine-2 receptor alpha) monoclonal antibody. Cancer Res 59:3128PubMedGoogle Scholar
  42. 42.
    Gallimore A, Sakaguchi S (2002) Regulation of tumor immunity by CD25+ T cells. Immunology 107:5CrossRefPubMedGoogle Scholar
  43. 43.
    Sutmuller RP, van Duivenvoorde LM, van Elsas A, Schumacher TN, Wildenberg ME, Allison JP, Toes RE, Offringa R, Melief CJ (2001) Synergism of cytotoxic T lymphocytes-associated antigen 4 blockade and depletion of CD25+ regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocytes responses. J Exp Med 194:823CrossRefPubMedGoogle Scholar
  44. 44.
    Jones E, Dahm-Vicker M, Simon AK, Green A, Powrie F, Cerundolo V, Gallimore A (2002) Depletion of CD25+ regulatory cells in suppression of melanoma growth and induction of autoreactivity in mice. Cancer Immunol 2:1Google Scholar
  45. 45.
    Wei-Zen W, Morris GP, Kong Yi-chi M (2004) Antitumor immunity and autoimmunity: a balancing act of regulatory T cells. Cancer Immunol Immunother 53:73CrossRefPubMedGoogle Scholar
  46. 46.
    Tanaka H, Tanaka J, Jorgen K, Shu S (2002) Depletion of CD4+CD25+ regulatory cells augments the generation of specific immune T cells in tumor-draining lymph nodes. J Immunother 25:207CrossRefGoogle Scholar
  47. 47.
    Golgher D, Jones E, Powrie F, Elliott T, Gallimore A (2002) Depletion of CD25+ regulatory cells uncovers immune responses to shared murine rejection antigens. Eur J Immunol 32:3267CrossRefPubMedGoogle Scholar
  48. 48.
    Woo EY, Yeh H, Chu CS, Schlienger K, Carroll RG, Riley JL, Kaiser LR, June CH (2002) Cutting edge: regulatory T cells from lung cancer patients inhibit autologous T cell proliferation. J Immunol 168:4272PubMedGoogle Scholar
  49. 49.
    Ghiringhelli F, Larmonier N, Schmitt E, Parcellier A, Cathelin D, Garrido C, Chauffert B, Solary E, Bonnotte B, Martin F (2004) CD4+D25+ regulatory T cells suppress tumor immunity sensitive to cyclophosphamide which allows immunotherapy in established tumors to be curative. Eur J Immunol 34:336CrossRefPubMedGoogle Scholar
  50. 50.
    Casares N, Arribillaga L, Sarobe P, Dotor J, Lopez-Diaz de Cerio A, Melero I, Prieto J, Borras-Cuesta F, Lasarte JJ (2003) CD4+/CD25+ regulatory cells inhibit activation of tumor primed CD4+ T cells with IFN-γ-dependent antiangiogenic activity, as well as long-lasting tumor immunity elicited by peptide vaccination. J Immunol 171:5931PubMedGoogle Scholar
  51. 51.
    Turk MJ, Guevara-Patino JA, Rizzuto GA, Engelhorn ME, Sakaguchi S, Houghton AN (2004) Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells. J Exp Med 20:771CrossRefGoogle Scholar
  52. 52.
    Liyanage UK, Moore TT, Joo HG, Tanaka Y, Hermann V, Doherty G, Drebin JA, Strasberg SM, Eberlein TJ, Goedegebuure PS, Linehan DC (2002) Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 169:2756PubMedGoogle Scholar
  53. 53.
    Somasundaram R, Jacob L, Swoboda R, Caputo L, Song H, Basak S, Monos D, Peritt D, Marincola F, Cai D, Birebent B, Bloome E, Kim J, Berencsi K, Mastrangelo M, Herlyn D (2002) Inhibition of cytolytic T lymphocyte proliferation by autologous CD4+/CD25+ regulatory T cells in a colorectal carcinoma patient is mediated by transforming growth factor-beta. Cancer Res 62:5267PubMedGoogle Scholar
  54. 54.
    Wolf AM, Wolf D, Steurer M, Gastl G, Gunsilius E, Grubeck-Loebenstein B (2003) Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res 9:606PubMedGoogle Scholar
  55. 55.
    Marshall NA, Christie LE, Munro LR, Culligan DJ, Johnston PW, Barker RN, Vickers MA (2003) Immunosuppressive regulatory T cells ate abundant in tumor lymphocytes of Hodgkins lymphoma. Blood 103:1755CrossRefPubMedGoogle Scholar
  56. 56.
    Javia LR, Rosenberg SA (2003) CD4+CD25+ suppressor lymphocytes in the circulation of patients immunized against melanoma antigens. J Immunother 26:85CrossRefPubMedGoogle Scholar
  57. 57.
    Terabe M, Berzofsky JA (2004) Immunoregulatory T cells in tumor immunity. Curr Opin Immunol 16:167CrossRefPubMedGoogle Scholar
  58. 58.
    Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, Zhu Y, Wei S, Kryczek I, Daniel B, Gordon A, Myers L, Lackner A, Disis ML, Knutson KL, Chen L, Zou W (2004) Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10:942CrossRefPubMedGoogle Scholar
  59. 59.
    Viguier M, Lemaitre F, Verola O, Cho MS, Gorochov G, Dubertret L, Bachelez H, Kourilsky P, Ferradini L (2004) Foxp3 expressing CD4+CD25+ regulatory T cells are overexpressed in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J Immunol 173:1444PubMedGoogle Scholar
  60. 60.
    Cozzo C, Larkin J III, Caton AJ (2003) Cutting edge: self-peptides drive the peripheral expansion of CD4+CD25+ regulatory T cells. J Immunol 171:5678PubMedGoogle Scholar
  61. 61.
    Thronton AM, Shevach EM (1998) CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp Med 188:287CrossRefPubMedGoogle Scholar
  62. 62.
    Itoh M, Takahashi T, Sakaguchi N, Kuniyasu Y, Shimizu J, Otsuka F, Sakaguchi S (1999) Thymus and autoimmunity: Production of CD25+CD4+ Naturally anergic and suppressive T cells as a key function of the thymus in maintaining immunologic self-tolerance. J Immunol 162:5317PubMedGoogle Scholar
  63. 63.
    Baecher-Allan C, Viglietta V, Hafler DA (2002) Inhibition of human CD(+)CD25(+high) regulatory T cell function. J Immunol 169:6210PubMedGoogle Scholar
  64. 64.
    Hoffmann P, Eder R, Kunz-Schughart LA, Andreesen R, Edinger R (2004) Large-scale in vitro expansion of polyclonal human CD4(+) CD25high regulatory T cells. Blood 104:895CrossRefPubMedGoogle Scholar
  65. 65.
    Thronton AM, Picirillo CA, Shevach EM (2004) Activation requirements for the induction of CD4+CD25+ T cell suppressor function. Eur J Immunol 24:366CrossRefGoogle Scholar
  66. 66.
    Thornton AM, Donovan EE, Piccirillo CA, Shevach EM (2004) Cutting edge: IL-2 is critically required for the in vitro activation of CD4+CD25+ T cell suppressor function. J Immunol 172:6519PubMedGoogle Scholar
  67. 67.
    Malek TR (2003) The main function of IL-2 is to promote the development of regulatory T cells. J Leukoc Biol 74:961CrossRefPubMedGoogle Scholar
  68. 68.
    Suri-Payer E, Cantor H (2001) Differential cytokine requirements for regulation of autoimmune gastritis and colitis by CD4+CD25+ T cells. J Autoimmun 16:115CrossRefPubMedGoogle Scholar
  69. 69.
    Asseman C, Mauze S, Leach M, Coffman Rl, Powrie F (1999) An essential role for interleukin-10 in the function of regulatory T cells that inhibit intestinal inflammation. J Exp Med 190:995CrossRefPubMedGoogle Scholar
  70. 70.
    Balkaid Y, Piccirillo CA, Mendez S, Shevach EM, Sachs DL (2002) CD4+CD25+ regulatory T cells control Leishmania major persistence and immunity. Nature 420:502CrossRefPubMedGoogle Scholar
  71. 71.
    Takahashi T, Tagami T, Yamazuki S, Ueda T, Shimizu J, Sakaguchi N, Mak TW, Sakaguchi S (2000) Dominant immunologic self-tolerance by CD4+CD25+ regulatory T cells constitutively expressing CTLA-4. J Exp Med 192:303CrossRefPubMedGoogle Scholar
  72. 72.
    Read S, Maimstrom S, Powrie F (2000) CTLA-4 plays an essential role in the function of CD4+CD25+ regulatory cells which control intestinal inflammation. J Exp Med 192:295CrossRefPubMedGoogle Scholar
  73. 73.
    Nakamura K, Kitani A, Strober W (2001) Cell contact-dependent immunosuppression by CD4+ CD25+ regulatory T cells is mediated by cell surface bound transformation growth factor beta. J Exp Med 194:629CrossRefPubMedGoogle Scholar
  74. 74.
    Annunziato F, Cosmi L, Liotta F, Lazzeri E, Manetti R, Vanini V, Romagnani P, Maggi E, Romagnani S (2002) Phenotype localization and mechanism of suppression of CD4+CD25+ human thymocytes. J Exp Med 196:379CrossRefPubMedGoogle Scholar
  75. 75.
    Levings MK, Bacchetta R, Schulz U, Roncarolo MG (2002) The role of IL-10 and TGF beta in the differentiation and effector function of T regulatory cells. Int Arch Allergy Immunol 129:263CrossRefPubMedGoogle Scholar
  76. 76.
    Piccirillo CA, Shevach EM (2001) Cutting edge: control of CD8+ T cell activation by CD4+CD25+ immunoregulatory cells. J Immunol 167:1137PubMedGoogle Scholar
  77. 77.
    Cederbom L, Hall H, Ivars F (2000) CD4+CD25+ regulatory T cells down-regulate co-stimulatory molecules on antigen-presenting cells. Eur J Immunol 30:1538CrossRefPubMedGoogle Scholar
  78. 78.
    Misra N, Bayry J, Lacroix-demazes S, Kazatcchkine MD, Kaveri SV (2004) Cutting Edge: Human CD4+CD25+ T cells restrain the maturation and antigen-presenting function of dendritic cells. J Immunol 172:4676PubMedGoogle Scholar
  79. 79.
    Gett AV, Sallusto F, Lanzavecchia A, Geginat J (2003) T cell fitness determined by signal strength. Nat Immunol 4:355CrossRefPubMedGoogle Scholar
  80. 80.
    Mehrotra S, Chhabra A, Chattopadhyay S, Dorsky DI, Chakraborty NG, Mukherji B (2004) Rescuing melanoma epitope specific cytolytic T lymphocytes from activation-induced cell death, by SP600125, an inhibitor of JNK: implications in cancer immunoterapy. J Immunol 173:6017PubMedGoogle Scholar
  81. 81.
    North RJ (1982) Cyclophosphamode-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells. J Exp Med 155:1063CrossRefPubMedGoogle Scholar
  82. 82.
    North RJ, Awwad M (1990) Elimination of cycling CD4+ suppressor T cells with an anti-mitotic drug releases non-cycling CD8+ T cells to cause regression of an advanced lymphoma. Immunology 71:90PubMedGoogle Scholar
  83. 83.
    Berd D, Mastrangelo MJ (1988) Effect of low dose cyclophosphamide on the immune system of cancer patients: depletion of CD4+, 2H4+ suppressor-inducer T -cells. Cancer Res 48:1671PubMedGoogle Scholar
  84. 84.
    Michiels J-P H, Reilly RT, Emens LA, Ercollini AM, Lei RY, Weintraub D, Okoye FI, Jaffee EM (2001) Cyclophosphamide, doxorubicin and paclitaxel enhance the antitumor immmune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice. Cancer Res 61:3689PubMedGoogle Scholar
  85. 85.
    Shevach EM (2002) CD4+CD25+ suppressor T cells: more questions than answers. Nat Rev Immunol 2:389PubMedGoogle Scholar
  86. 86.
    Cohn M (2004) Whither T-suppressors: if they did not exist would we have to invent them? Cell Immunol 227:81CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2005

Authors and Affiliations

  • Subhasis Chattopadhyay
    • 1
  • Nitya G. Chakraborty
    • 1
  • Bijay Mukherji
    • 1
  1. 1.University of Connecticut School of MedicineFarmingtonUSA

Personalised recommendations